Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope-Reference-Cited by-同舟云学术

Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope

Published:2016-09-09 Issue:10 Volume:5 Page:e1216290
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Baumgaertner P.¹,Costa Nunes C.¹,Cachot A.¹,Maby-El Hajjami H.¹²,Cagnon L.²,Braun M.¹,Derré L.³,Rivals J.-P.⁴,Rimoldi D.¹,Gnjatic S.⁵,Abed Maillard S.²,Marcos Mondéjar P.¹²,Protti M. P.⁶⁷,Romano E.²,Michielin O.¹²,Romero P.¹²,Speiser D. E.¹²,Jandus C.¹

Affiliation:

1. Ludwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland

2. Department of Oncology, University Hospital Center (CHUV), Lausanne, Switzerland

3. Urology Research Unit, Urology Department, University Hospital Center (CHUV), Lausanne, Switzerland

4. Department of Otorhinolaryngology – Head and Neck Surgery, CHUV, University of Lausanne, Switzerland

5. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA

6. Tumor Immunology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

7. Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

Funder

Cancer Research Institute (USA), Ludwig Cancer Research (USA), the Cancer Vaccine Collaborative (USA), Atlantic Philanthropies (USA), the Wilhelm Sander-Foundation (Germany), Swiss Cancer Research

the Swiss National Science Foundation

SwissTransMed

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2016.1216290

Reference50 articles.

1. The Present and Future of Peptide Vaccines for Cancer

2. New Generation Vaccine Induces Effective Melanoma-Specific CD8+T Cells in the Circulation but Not in the Tumor Site

3. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909